resumo
- The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
- Visão geral
- Pesquisas
- Identidade
- Informação adicional documento
- Ver Todos
Visão geral
autores
data de publicação
- janeiro 2010
publicada em
- Inflammation Research Revista